Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacokinetics and Pharmacodynamics of a Novel Formulation of Furosemide Administered as a Single Subcutaneous Injection.

Clinical therapeutics·2025

Same author

Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF).

JACC. Heart failure·2024

Same author

Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide.

Medical devices (Auckland, N.Z.)·2024

Same author

Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations.

ClinicoEconomics and outcomes research : CEOR·2023

Same author

Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study.

Future cardiology·2023

Same author

From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion.

Structural heart : the journal of the Heart Team·2023

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Dysglycaemias and fluoroquinolones.

Roshan J Lewis¹, John F Mohr

¹Department of Internal Medicine, Division of Infectious Diseases and The Center for Emerging and Re-emerging Pathogens, The University of Texas Health Science Center at Houston, Houston, TX, USA.

|March 28, 2008

Summary

Fluoroquinolones, popular antibacterials, can cause severe blood sugar changes like hyperglycemia and hypoglycemia. Understanding risk factors helps minimize these adverse drug events.

Area of Science:

Pharmacology
Endocrinology
Infectious Diseases

Background:

Fluoroquinolones are widely used antibacterials with broad-spectrum activity and convenient dosing.
While generally safe, some fluoroquinolones are linked to severe adverse drug reactions, including dysglycaemia (hyperglycemia and hypoglycemia).
Gatifloxacin shows a higher frequency of dysglycaemia, but other fluoroquinolones also report these events.

Purpose of the Study:

To review the association between fluoroquinolone use and dysglycaemic events.
To explore the mechanisms and risk factors contributing to fluoroquinolone-induced hyperglycemia and hypoglycemia.
To inform safer clinical utilization of fluoroquinolones.

Main Methods:

Review of existing literature on fluoroquinolone-associated dysglycaemia.

More Related Videos

Highly Sensitive and Rapid Fluorescence Detection with a Portable FRET Analyzer

Highly Sensitive and Rapid Fluorescence Detection with a Portable FRET Analyzer

Published on: October 1, 2016

Related Experiment Videos

Last Updated: Jul 6, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Highly Sensitive and Rapid Fluorescence Detection with a Portable FRET Analyzer

Highly Sensitive and Rapid Fluorescence Detection with a Portable FRET Analyzer

Published on: October 1, 2016

Analysis of retrospective studies identifying risk factors for adverse events.

Examination of proposed mechanisms involving ATP-sensitive K+ channels and anti-insulin hormones.

Main Results:

Dysglycaemia, including hypoglycemia (early onset, insulin-related) and hyperglycemia (later onset, unclear mechanism), is an adverse effect of fluoroquinolones.
Risk factors for dysglycaemia have been identified in retrospective studies.
The effect appears dose-related and may involve fluoroquinolone affinity for ATP-sensitive K+ channels and drug concentration in at-risk patients.

Conclusions:

Fluoroquinolone-associated dysglycaemia is a significant concern requiring careful patient monitoring.
Understanding specific drug affinities and patient risk factors is crucial for mitigating adverse events.
Optimizing fluoroquinolone use based on identified risk factors can improve patient safety and minimize dysglycaemic episodes.